| 摘要 |
A pharmaceutical composition comprises: a plurality of first particulates comprising a 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, preferably a triptan selected from sumatriptan, almotriptan, frovatriptan, eletriptan, rizatriptan or naratriptan; and a plurality of second particulates comprising an antiemetic or a pharmaceutically acceptable salt thereof, preferably promethazine, characterised in that the weight of the plurality of first particulates to the plurality of second particulates is from about 3:1 to about 5:1 respectively. Preferably the plurality of first particulates comprises about 50-150mg of the 5HT1B receptor agonist or pharmaceutically acceptable salt thereof; about 1-10mg of polyvinylpyrrolidone; about 50-100mg microcrystalline cellulose; about 1-10mg croscarmellose sodium; about 0.1-5mg of magnesium stearate; and a coating material; and the plurality of second particulates comprises: about 10-50mg antiemetic or a pharmaceutically acceptable salt thereof; about 10-50mg microcrystalline cellulose; about 0.1-5mg of croscarmellose sodium and a coating material. Preferably the coating material is polyvinyl alcohol. The composition is useful in the treatment of headache, headache-associated symptoms such as nausea or vomiting, or adverse effects associated with triptan administration. |
